Evidence map›Paper›PMID 37462801›Full record

ArticleJournal of neuro-oncology2023

Signal-transducing adaptor protein 1 (STAP1) in microglia promotes the malignant progression of glioma.

Xinyu Yang, Chunxia Ji, Ying Qi, Jianhan Huang, Lang Hu, Yuan Zhou, Liping Zou, Yi Xia, Feng Tan, Yu Yao and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Xinyu YangDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Chunxia JiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Ying QiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Jianhan HuangDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Lang HuDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yuan ZhouDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Liping ZouDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Yi XiaDepartment of Pathology, Huashan Hospital, Fudan University, Shanghai, China.
Feng TanSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yu YaoDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. yu_yao@fudan.edu.cn.
Di ChenDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. dichen18@fudan.edu.cn.ORCID http://orcid.org/0000-0002-9497-3588
Fudan University · CNShanghai Medical College of Fudan University · CNWenzhou Medical University · CN

Funding

Clinical Research Plan of SHDC SHDC2020CR2018BNational Key R&D Program of China 2022YFC3401600National Natural Science Foundation of China 91959112Science and Technology Innovation Plan of the Science and Technology Commission of Shanghai Municipality 201409001600Shanghai Anticancer Association EYAS PROJECT SACA-CY1A01
6 · The paper itself

Abstract

backgroundGlioma is the most malignant primary brain tumor with a poor survival time. The tumour microenvironment, especially glioma-associated microglia/macrophages (GAMs), plays an important role in the pathogenesis of glioma. Currently, microglia (CD11b

methodsThe Cancer Genome Atlas and Chinese Glioma Genome Atlas databases were used to investigate the association between STAP1 mRNA levels and clinical parameters (grades, mutations in isocitrate dehydrogenase, and overall survival). RNA-sequencing, qRT-PCR, Western blotting, immunohistochemistry and immunofluorescence analyses were performed to detect the expression level of STAP1 and related proteins. BV-2 cells were used to construct a STAP1-overexpressing cell line. Phagocytosis of BV-2 cells was assessed by flow cytometry and fluorescence microscopy. C57BL/6 mice were used to establish orthotopic and subcutaneous glioma mouse models. Glioma growth was monitored by bioluminescence imaging.

resultsSTAP1 expression in glioma-associated microglia is positively correlated with the degree of malignancy and poor prognosis of glioma. Moreover, STAP1 may promote M2-like polarisation by increasing ARG1 expression and inhibiting microglial phagocytosis of microglia. Increased ARG1 may be associated with the IL-6/STAT3 pathway. Impaired phagocytosis may be associated with decreased cofilin and filopodia.

conclusionSTAP1 is positively associated with the degree of glioma malignancy and may represent a potential novel therapeutic target for glioma.

Indexed as

Brain NeoplasmsGliomaAnimalsCell Line, TumorMacrophagesMiceMice, Inbred C57BLMicrogliaTumor MicroenvironmentGliomaMicrogliaPolarisationSTAP1

Identifiers

PMID37462801
PMCPMC10462508
OpenAlexW4384626211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.